Rinat Neuroscience Corporation

Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs, including:

Rinat was founded in 2001 by Arnon Rosenthal,[12][13] who was also Rinat's president, chief scientific office and board director, and Patrick Lynn,[14] following a broad licensing agreement with Genentech,[15] and was acquired by Pfizer in 2006 for approximately $500M.[16][17] Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco.[18]

• Tanezumab (codenamed RN624),[1][2] a monoclonal antibody against nerve growth factor for the treatment of pain
• Ponezumab (codenamed RN1219),[3] a monoclonal antibody against beta amyloid for the treatment of Alzheimer's disease
• Fremanezumab (codenamed TEV-48125, RN307 and LBR-101),[4][5][6]